CD8A and neoplasm: Moreover, the therapy with vIL-2 demonstrated to be safe in the treated animals as monotherapy, and here we did not observe any systemic adverse reactions due to the treatment or at the local site of the virus injections Here, the potent pro-inflammatory response mainly mediated by the increased cytotoxicity of NK cell, CD4+ T and CD8+ T cells have been able to outperform the rapid tumor growth and TReg cell immunosuppression in the combination treated animals.